Clinical report: Sanofi data advances pair of autoimmune disease mechanisms

New clinical data for rilzabrutinib and frexalimab from Sanofi (Euronext:SAN; NASDAQ:SNY) advance a pair of new autoimmune disease mechanisms, and the pharma’s strategy for building pipeline-in-a-product assets to treat inflammatory diseases.

The company said it plans to submit regulatory applications in the U.S. and Europe by year-end for covalent, reversible BTK inhibitor rilzabrutinib, after the therapy met the primary endpoint in the Phase III LUNA 3 study to treat chronic immune thrombocytopenia (ITP). Sanofi did not disclose data, so it’s not clear yet how rilzabrutinib will compare with other therapies in development for the indication, such as Vyvgart efgartigimod from Argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)...